DUBLIN--(BUSINESS WIRE)--The "Cough - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H1 2020, provides an overview of the Cough (Respiratory) pipeline landscape. The guide provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 10, 5, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Scope of the report:
- The guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
- The guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
- The guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The guide encapsulates all the dormant and discontinued pipeline projects.
- The guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)
Key report benefits:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Cough - Overview
- Cough - Therapeutics Development
- Cough - Therapeutics Assessment
- Cough - Companies Involved in Therapeutics Development
- Cough - Drug Profiles
- Cough - Dormant Projects
- Cough - Discontinued Products
- Cough - Product Development Milestones
Companies Mentioned
- Algernon Pharmaceuticals Inc
- Alitair Pharmaceuticals Inc
- Antheia Inc
- Asana BioSciences LLC
- Axalbion SA
- Bayer AG
- Beijing Tide Pharmaceutical Co Ltd
- Charleston Laboratories Inc
- Conrig Pharma ApS
- Develco Pharma Schweiz AG
- Evotec SE
- Grunenthal GmbH
- Hyundai Pharmaceutical Co Ltd
- Korea United Pharm Inc
- Merck & Co Inc
- NeRRe Therapeutics Ltd
- Nocion Therapeutics Inc
- Nuformix Plc
- Orbis Biosciences Inc
- PhytoHealth Corp
- Roivant Sciences Ltd
- Shionogi & Co Ltd
- SolAeroMed Inc
- Trevi Therapeutics Inc
- Tris Pharma Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/14a7mj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
